Professor Simon J Bowman BSc MBBS PhD FRCP

Simon Bowman

Institute of Inflammation and Ageing
Honorary Professor of Rheumatology

Contact details

Institute of Inflammation and Ageing
College of Medical and Dental Sciences
University of Birmingham
B15 2TT

Simon Bowman is an Honorary Professor of Rheumatology within the Institute of Inflammation and Ageing at the University of Birmingham. He is part-funded by the Birmingham Biomedical Research Centre.

Professor Bowman has an active NHS clinical practice, both as an Honorary Consultant Rheumatologist in the Sjogren’s Clinic at University Hospitals Birmingham NHS Trust and more broadly as a Consultant Rheumatologist in general NHS rheumatology practice at Milton Keynes University Hospital NHS Trust.


  • FRCP, Royal College of Physicians UK, 2000
  • CCST, JCHMT, 1997 
  • PhD, University of London, 1995
  • MRCP, Royal College of Physicians UK, 1989
  • MB BS, University of London, 1986
  • BSc (1st class Hons), University of London, 1983 


Professor Bowman qualified from University College London Hospitals in 1986 and achieved Membership of the Royal College of Physicians in 1989 and Fellowship in 2000. From 1991-1994 he was awarded a Medical Research Council PhD studentship at UMDS Guy’s Hospital studying the immunogenetic and T-cell receptor repertoire in patients with Felty’s syndrome and receiving his PhD in 1995.

He then did further clinical training at the Nuffield Orthopaedic Centre in Oxford 1994-1996 and was subsequently awarded a postdoctoral MRC Clinician Scientist Fellowship. During this period he moved to take up a Senior Lectureship at the University of Birmingham and Honorary Consultant Post at Birmingham Heartlands Hospital and University Hospitals Birmingham developing his clinical and research interest in Sjogren’s Syndrome. From 2003-2017 he worked as an NHS Consultant based at University Hospitals Birmingham before taking up his current roles.

Postgraduate supervision

Professor Bowman has supervised a number of PhD studentships and has taught undergraduate and postgraduate medical students throughout his professional career.


Professor Bowman’s research has been focused on Sjogren’s Syndrome; specifically on developing clinical tools to support clinical trials in this condition for which there are currently no disease-modifying treatments.

He is currently leading workpackage 8 of the €15.4 million EU funded ‘New Clinical Endpoints in pSS: an interventional trial based on stratifying patients (NECESSITY). 2019-2025’ led by Professor Xavier Mariette (Paris, France).

Professor Bowman led the ARUK funded TRACTISS trial of Rituximab in primary Sjogren’s Syndrome along with Professor Paul Emery and Professor Costantino Pitzalis which was the first UK led trial of a biologic therapy in this condition (published 2017). He has provided advice on trial design to a number of major pharmaceutical companies investigating new therapies for use in Sjogren’s Syndrome for patient benefit. Samples and data from the TRACTISS Trial has continued to generate further research in collaboration with Professor Michele Bombardieri and colleagues at Queen Mary’s University of London and other collaborators internationally.

In collaboration with Professor Wan-Fai Ng of the University of Newcastle, UK, Professor Bowman was involved in the establishment of the MRC funded UK Primary Sjogren’s Syndrome Registry in 2010. and has also been a member of the FOREUM consortium on developing stratified medicine approaches to primary Sjogren’s Syndrome.

He was a leading contributor to the development of the 2016 American College of Rheumatology-European League against Rheumatism revised classification criteria for Sjogren’s Syndrome and to the development of the EULAR Sjogren’s Syndrome Disease Activity Index (ESSDAI) and Patient Reported Outcome (ESSPRI) measures that are in standard use today.

He also worked with Professor David Booth and many UK clinical colleagues prior to that in 2003-2004 to develop the Profile of Fatigue and Discomfort – Sicca Symptoms Inventory (PROFAD-SSI) that was the forerunner of the ESSPRI.

Other activities

  • Research and Development Lead at Milton Keynes University Hospital NHS Trust.
  • Deputy Treasurer of the Royal College of Physicians since 2016 and Harveian Librarian from 2016-2020.
  • Elected President of the British Society for Rheumatology in 2014-2016 having previously been Chair of the Education and Training Committee from 2010-2013.
  • From 2007-2013 Professor Bowman was Trustee and Medical President of the British Sjogren’s Syndrome Association (BSSA) which is the UK patient charity for Sjogren’s Syndrome.

Other activities have also included

  • Chair of South Birmingham Research Ethics Committee 2009-2016.
  • West Midlands Representative on the NHS England Clinical Reference Group for Specialised Rheumatology 2013-2016.
  • Member: Scientific Strategy Committee ARUK (2014-2016); ARC Autoimmune Rheumatic Disease Subcommittee Clinical Trials Initiative (2007-2009) (also DMEC Vice-Chair).
  • Sjögren’s Syndrome Foundation of America Medical Advisory Board (2005-2008).


Publications from 2019-mid 2021

Retamozo S, Baldini C, Bootsma H, De Vita S, Dörner T, Fisher BA, Gottenberg JE, Hernández-Molina G, Kocher A, Kostov B, Kruize AA, Mandl T, Ng WF, Seror R, Shoenfeld Y, Sisó-Almirall A, Tzioufas AG, Vissink A, Vitali C, Bowman SJ, Mariette X, Ramos-Casals M, Brito-Zerón P. Therapeutic Recommendations for the Management of Older Adult Patients with Sjogren's Syndrome. Drugs Aging. 2021 Apr;38(4):265-284.

Price E, Allen A, Rauz S, Tappuni A, Sutcliffe N, Bombardieri M, Carty S, Ciurtin C, Crampton B, Duncalfe L, Fisher B, Glennon P, Hackett KL, Larkin G, Ng WF, Ramanan AV, Rassam S, Walsh SB, Bowman S. The management of Sjogren's syndrome: British Society for Rheumatology guideline scope. Rheumatology (Oxford). 2021 May 14;60(5):2122-

Machowicz A, Hall I, de Pablo P, Rauz S, Richards A, Higham J, Poveda-Gallego A, Imamura F, Bowman SJ, Barone F, Fisher BA. Mediterranean diet and risk of Sjogren's syndrome. Clin Exp Rheumatol. 2020 Jul-Aug;38 Suppl 126(4):216-221.

Seror R, Bowman S. Outcome Measures in Primary Sjogren's Syndrome. Arthritis Care Res (Hoboken). 2020 Oct;72 Suppl 10:134-149. Review.

Pontarini E, Murray-Brown WJ, Croia C, Lucchesi D, Conway J, Rivellese F, Fossati-Jimack L, Astorri E, Prediletto E, Corsiero E, Romana Delvecchio F, Coleby R, Gelbhardt E, Bono A, Baldini C, Puxeddu I, Ruscitti P, Giacomelli R, Barone F, Fisher B, Bowman SJ, Colafrancesco S, Priori R, Sutcliffe N, Challacombe S, Carlesso G, Tappuni A, Pitzalis C, Bombardieri M. Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjogren's syndrome with ectopic germinal centres and MALT lymphoma. Ann Rheum Dis. 2020 Dec;79(12):1588-1599.

Juarez M, Diaz N, Johnston GI, Nayar S, Payne A, Helmer E, Cain D, Williams P, Devauchelle-Pensec V, Fisher BA, Giacomelli R, Gottenberg JE, Guggino G, Kvarnström M, Mariette X, Ng WF, Rosas J, Sánchez Bursón J, Triolo G, Barone F, Bowman SJ. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjogren's syndrome. Rheumatology (Oxford). 2021 Mar 2;60(3):1364-1375. Clinical Trial.

Traianos EY, Locke J, Lendrem D, Bowman S, Hargreaves B, Macrae V; UK primary Sjögren’s syndrome registry, Tarn JR, Ng WF. Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjogren's syndrome. Rheumatol Int. 2020 Apr;40(4):541-548.

Brito-Zerón P, Retamozo S, Kostov B, Baldini C, Bootsma H, De Vita S, Dörner T, Gottenberg JE, Kruize AA, Mandl T, Ng WF, Seror R, Tzioufas AG, Vitali C, Bowman S, Mariette X, Ramos-Casals M. Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjogren's syndrome. RMD Open. 2019 Oct 28;5(2):e001064. Review.

Ramos-Casals M, Brito-Zerón P, Bombardieri S, Bootsma H, De Vita S, Dörner T, Fisher BA, Gottenberg JE, Hernandez-Molina G, Kocher A, Kostov B, Kruize AA, Mandl T, Ng WF, Retamozo S, Seror R, Shoenfeld Y, Sisó-Almirall A, Tzioufas AG, Vitali C, Bowman S, Mariette X; EULAR-Sjögren Syndrome Task Force Group. EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies. Ann Rheum Dis. 2020 Jan;79(1):3-18.

Jousse-Joulin S, Gatineau F, Baldini C, Baer A, Barone F, Bootsma H, Bowman S, Brito-Zerón P, Cornec D, Dorner T, de Vita S, Fisher B, Hammenfors D, Jonsson M, Mariette X, Milic V, Nakamura H, Ng WF, Nowak E, Ramos-Casals M, Rasmussen A, Seror R, Shiboski CH, Nakamura T, Vissink A, Saraux A, Devauchelle-Pensec V. Weight of salivary gland ultrasonography compared to other items of the 2016 ACR/EULAR classification criteria for Primary Sjogren's syndrome. J Intern Med. 2020 Feb;287(2):180-188.

Grigoriadou S, Chowdhury F, Pontarini E, Tappuni A, Bowman SJ, Bombardieri M. B cell depletion with rituximab in the treatment of primary Sjogren's syndrome: what have we learnt? Clin Exp Rheumatol. 2019 May-Jun;37 Suppl 118(3):217-224. Review.

Davies K, Mirza K, Tarn J, Howard-Tripp N, Bowman SJ, Lendrem D; UK Primary Sjögren’s Syndrome Registry, Ng WF. Fatigue in primary Sjogren's syndrome (pSS) is associated with lower levels of proinflammatory cytokines: a validation study. Rheumatol Int. 2019 Nov;39(11):1867-1873.

Seror R, Rauz S, Gosset M, Bowman SJ. Disease activity and patient reported outcome measures in Sjogren's - what are the best tools to evaluate? Rheumatology (Oxford). 2019 Jun 24:kez201.

Nayar S, Campos J, Smith CG, Iannizzotto V, Gardner DH, Mourcin F, Roulois D, Turner J, Sylvestre M, Asam S, Glaysher B, Bowman SJ, Fearon DT, Filer A, Tarte K, Luther SA, Fisher BA, Buckley CD, Coles MC, Barone F. Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology. Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13490-13497.

Hackett KL, Davies K, Tarn J, Bragg R, Hargreaves B, Miyamoto S, McMeekin P, Mitchell S, Bowman S, Price EJ, Pease C, Emery P, Andrews J, Lanyon P, Hunter J, Gupta M, Bombardieri M, Sutcliffe N, Pitzalis C, McLaren J, Cooper A, Regan M, Giles I, Isenberg D, Vadivelu S, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots R, Gendi N, Akil M, Griffiths B, Lendrem DW, Ng WF. Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjogren's syndrome. RMD Open. 2019 Apr 24;5(1):e000885.

Nayar S, Campos J, Smith CG, Iannizzotto V, Gardner DH, Colafrancesco S, Pipi E, Kollert F, Hunter KJ, Brewer C, Buckley CD, Bowman SJ, Priori R, Valesini G, Juarez M, Fahy WA, Fisher BA, Payne A, Allen RA, Barone F. Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjogren's syndrome. Ann Rheum Dis. 2019 Feb;78(2):249-260.

Fisher BA, Emery P, Pitzalis C, Bombardieri M, Bowman SJ. Response to: Can ultrasound of the major salivary glands assess histopathological changes induced by treatment with rituximab in primary Sjogren's syndrome? Ann Rheum Dis. 2019 Apr;78(4):e28.

See Simon Bowman's publications on the University of Birmingham research gateway.